Press Release Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ Aug 14
Press Release Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Aug 12
Press Release Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants Aug 12
Press Release Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 Aug 6